Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
It's marketed under brand names like Wegovy for weight management and Ozempic for type 2 diabetes
Research has examined its role in: GHRH receptor binding, Gs/adenylate cyclase activation, and cAMP/PKA signalling pathway studies Physiological pulsatile GH secretion modelling and somatotroph biology investigations GH and IGF-1 axis regulation and downstream anabolic signalling research DPP-4 resistance profiling and GHRH analogue structural pharmacology studies Somatotroph proliferation, GH mRNA transcription, and pituitary reserve research GH pulsatility architecture pulse amplitude, frequency, trough levels, and inter-pulse intervals Somatostatin feedback dynamics and GHRH/somatostatin interplay modelling Metabolic pathway research lipid oxidation, glucose homeostasis, and anabolic signalling GH axis ageing, somatopause, and GHRH pulse amplitude decline studies Dual-pathway synergy research when combined with GHS-R1a agonists such as Ipamorelin Comparative GHRH analogue pharmacology Sermorelin, Tesamorelin, and CJC-1295 DAC CJC-1295 Without DAC and Pituitary Somatotroph Biology Research in GHRH knockout mice using the CJC-1295 backbone demonstrated that administration caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred as confirmed by immunohistochemistry establishing that the tetrasubstituted GHRH scaffold acts not only on acute GH release but also on transcriptional upregulation of GH gene expression and pituitary somatotroph reserve, findings directly relevant to the no-DAC variants receptor biology
These comprehensive benefits make IGF-1 LR3 a valuable tool for optimizing physical performance and overall well-being when traditional approaches fall short
It also slows down how quickly food leaves your stomach, making you full longer and reducing cravings
Allergan Aesthetics says it has been studying the intersection of medical weight loss and aesthetic medicine since 2022, including research presented at the 2025 American Society for Dermatologic Surgery Annual Meeting and a January 2026 publication in Aesthetic Surgery Journal Open Forum examining nonsurgical facial treatments for patients using GLP-1 receptor agonists
key tools for people stuck in the cycle of fatigue and weight gain
